pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

65 catalysts · 27 8k filing · 8 phase 2 initiation · 6 phase 2 completion · 4 phase iv trial initiation · 4 phase 3 completion · 3 phase 1 results

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 74 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 16 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-04-24×to 2026-04-24×clear all
type
  • 8k filing27
  • phase 2 initiation8
  • phase 2 completion6
  • phase iv trial initiation4
  • phase 3 completion4
  • phase 1 results3
phase 1 completion
2
  • phase 1 2 completion2
  • patent expiry2
  • drug expiry2
  • therapy area
    • Oncology9
    • Infectious Disease5
    • Dermatology4
    • Pulmonology3
    • Women's Health3
    • Immunology3
    • Pain3
    • Ophthalmology1

    Week of Apr 20, 2026

    50
    ›Apr 24, 2026patent expiry109d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026patent expiry109d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026drug expiry109d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry109d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 1 completion109d agoLarkspur Biosciences Inc — undisclosed drug (Phase I Trial Completion)undisclosed drug

    Therapy area: Undisclosed. Indication: Unspecified

    full page →undisclosed drug →source: globaldata
    ›Apr 24, 2026phase 1 completion109d agoAkeso Inc — AK-132 (Phase I Trial Completion)AK-132

    Therapy area: Oncology. Indication: Solid Tumor

    full page →AK-132 →source: globaldata
    ›Apr 24, 2026phase 1 initiation109d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

    Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

    full page →CMSD-001 →source: globaldata
    ›Apr 24, 2026phase 1 results109d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

    Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

    full page →viral-specific T-cells →source: globaldata
    ›Apr 24, 2026phase 1 results109d agoMedicus Pharma Ltd — teverelix (Phase I Trial Results)teverelix

    Therapy area: Women's Health. Indication: Endometriosis

    full page →teverelix →source: globaldata
    ›Apr 24, 2026phase 1 results109d agoMedicus Pharma Ltd — teverelix (Phase I Trial Results)teverelix

    Therapy area: Women's Health. Indication: Endometriosis

    full page →teverelix →source: globaldata
    ›Apr 24, 2026phase 1 2 completion109d agoSt. Paul's Hospital — methoxyflurane (Phase I/II Trial Completion)methoxyflurane

    Therapy area: Central Nervous System, Ear Nose Throat Disorders. Indication: Pain, Rhinosinusitis

    full page →methoxyflurane →source: globaldata
    ›Apr 24, 2026phase 1 2 completion109d agoUniversity of Otago — ketamine (Phase I/II Trial Completion)ketamine

    Therapy area: Central Nervous System. Indication: Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD)

    full page →ketamine →source: globaldata
    ›Apr 24, 2026phase 1 2 initiation109d agoMayo Clinic — eflornithine hydrochloride (Phase I/II Trial Initiation)eflornithine hydrochloride

    Therapy area: Oncology. Indication: Anaplastic Astrocytoma, Glioblastoma Multiforme (GBM), High-Grade Glioma, Low-Grade Astrocytoma, Malignant Glioma, Oligodendroglioma

    full page →eflornithine hydrochloride →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoUniversity Health Network — bevacizumab (Phase II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoXijing Hospital — propofol (Phase II Trial Completion)PROPOFOL

    Therapy area: Central Nervous System. Indication: Delirium

    full page →PROPOFOL →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoKothiwal Dental College and Research Centre — platelet rich plasma (Phase II Trial Completion)platelet rich plasma

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →platelet rich plasma →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

    Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

    full page →lixudebart →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoSwinburne University of Technology — dronabinol (Phase II Trial Completion)dronabinol

    Therapy area: Central Nervous System. Indication: Anxiety Disorders, Insomnia, Pain

    full page →dronabinol →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoJapanese Governmental Office — capecitabine (Phase II Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoHuashan Hospital Fudan University — JMKX-003002 (Phase II Trial Initiation)JMKX-003002

    Therapy area: Nutritional Disorders. Indication: Hyperphosphatemia

    full page →JMKX-003002 →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoBaseCure Therapeutics Ltd — BC-006 (Phase II Trial Initiation)BC-006

    Therapy area: Metabolic Disorders. Indication: Obesity

    full page →BC-006 →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoRajiv Gandhi Government Post-Graduate Ayurvedic College — ayurvedic medicine (Phase II Trial Initiation)ayurvedic medicine

    Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

    full page →ayurvedic medicine →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoSRM Kattankulathur Dental College and Hospital — human placental extract (Phase II Trial Initiation)human placental extract

    Therapy area: Dermatology. Indication: Wounds

    full page →human placental extract →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoCommand Hospital Western Command — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoDasan Pharmaceutical Co Ltd — (acetaminophen + tramadol hydrochloride) (Phase II Trial Initiation)(acetaminophen + tramadol hydrochloride)

    Therapy area: Central Nervous System. Indication: Pain

    full page →(acetaminophen + tramadol hydrochloride) →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoSri Devaraj Urs Academy of Higher Education and Research — iron (Phase II Trial Initiation)iron

    Therapy area: Hematological Disorders. Indication: Iron Deficiency Anemia

    full page →iron →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoPierc Parul University — ayurvedic medicine (Phase II Trial Initiation)ayurvedic medicine

    Therapy area: Hematological Disorders, Mouth and Dental Disorders. Indication: Dental Caries, Gingivitis, Hemorrhage, Periodontitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 24, 2026phase 2 results109d agoCity of Hope — Methotrexate Teva (Phase II Trial Results)Maxtrex

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

    full page →Maxtrex →source: globaldata
    ›Apr 24, 2026phase 2 3 initiation109d agoCentral South University Xiangya Hospital 3 — HL-1186 (Phase II/III Trial Initiation)HL-1186

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →HL-1186 →source: globaldata
    ›Apr 24, 2026phase 2 3 initiation109d agoPostgraduate Institute of Medical Education and Research — acetaminophen (Phase II/III Trial Initiation)acetaminophen ER

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →acetaminophen ER →source: globaldata
    ›Apr 24, 2026phase 3 completion109d agoChong Kun Dang Pharmaceutical Corp. — CKD-398 (Phase III Trial Completion)CKD-398

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →CKD-398 →source: globaldata
    ›Apr 24, 2026phase 3 completion109d agoImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd — timdarpacept (Phase III Trial Completion)timdarpacept

    Therapy area: Oncology. Indication: Chronic Myelomonocytic Leukemia (CMML)

    full page →timdarpacept →source: globaldata
    ›Apr 24, 2026phase 3 completion109d agoBioClever 2005 SL — minoxidil (Phase III Trial Completion)minoxidil

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →minoxidil →source: globaldata
    ›Apr 24, 2026phase 3 completion109d agoShriners Hospitals for Children — bupivacaine ER (Phase III Trial Completion)bupivacaine

    Therapy area: Central Nervous System, Mouth and Dental Disorders. Indication: Post-Operative Pain, Unspecified Mouth and Dental Disorders

    full page →bupivacaine →source: globaldata
    ›Apr 24, 2026phase iv trial initiation109d agoPeople's College of Medical Sciences & Research Centre — formoterol (Phase IV Trial Initiation)formoterol

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →formoterol →source: globaldata
    ›Apr 24, 2026phase iv trial initiation109d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

    Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

    full page →melatonin →source: globaldata
    ›Apr 24, 2026phase iv trial initiation109d agoIxoreal Biomed Pvt Ltd — shatavari (Phase IV Trial Initiation)shatavari

    Therapy area: Hormonal Disorders, Women's Health. Indication: Menstrual Disorders, Unspecified Hormonal Disorders

    full page →shatavari →source: globaldata
    ›Apr 24, 2026phase iv trial initiation109d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →carboxymethylcellulose →source: globaldata
    ›Apr 24, 20268k filing109d agoHumacyte, Inc. (HUMA, HUMAW) — 8-K filingHumacyte, Inc.

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d ago$ALT — Altimmune, Inc. (ALT) — 8-K filingAltimmune, Inc.

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d agoNEXGEL, INC. (NXGL, NXGLW) — 8-K filingNEXGEL, INC.

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d agoNewAmsterdam Pharma Co N.V. (NAMS, NAMSW) — 8-K filingNewAmsterdam Pharma Co N.V.

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d ago$PDSB — PDS Biotechnology Corp (PDSB) — 8-K filingPDS Biotechnology Corp

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d ago$NVCR — NovoCure Ltd (NVCR) — 8-K filingNovoCure Ltd

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d agoProfusa, Inc. (PFSA, NVACW) — 8-K filingProfusa, Inc.

    Items: 1.01, 2.03, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d ago$ONCO — Onconetix, Inc. (ONCO) — 8-K filingOnconetix, Inc.

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d agoMedicus Pharma Ltd. (MDCX, MDCXW) — 8-K filingMedicus Pharma Ltd.

    Items: 1.01, 3.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d ago$QTTB — Q32 Bio Inc. (QTTB) — 8-K filingQ32 Bio Inc.

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d agoScorpius Holdings, Inc. — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing109d ago$XBIO — Xenetic Biosciences, Inc. (XBIO) — 8-K filingXenetic Biosciences, Inc.

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ← prev
    page 1 of 2
    next →
    $PFSA1.7200-9.47%
    $NAMSW19.000.00%
    $NVCR20.05+28.74%
    $NXGLW0.0285-7.47%
    $ALT3.0500-0.97%
    $HUMAW0.00990.00%
    $PDSB0.7311-5.16%
    $ONCO0.8867+0.75%
    $MDCX0.3842+2.59%
    $MDCX0.3842+2.59%
    $MDCX0.3842+2.59%
    $QTTB15.39+2.06%
    $XBIO2.6850+0.56%